{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:37:53Z","timestamp":1792219073065,"version":"4.4.0"},"reference-count":279,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) block inhibitory molecules, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its ligand, programmed cell death protein ligand 1 (PD-L1) and enhance antitumor T-cell activity. ICIs provide clinical benefits in a percentage of patients with advanced cancers, but they are usually associated with a remarkable spectrum of immune-related adverse events (irAEs) (e.g., rash, colitis, hepatitis, pneumonitis, endocrine, cardiac and musculoskeletal dysfunctions). Particularly patients on combination therapy (e.g., anti-CTLA-4 plus anti-PD-1\/PD-L1) experience some form of irAEs. Different mechanisms have been postulated to explain these adverse events. Host factors such as genotype, gut microbiome and pre-existing autoimmune disorders may affect the risk of adverse events. Fatal ICI-related irAEs are due to myocarditis, colitis or pneumonitis. irAEs usually occur within the first months after ICI initiation but can develop as early as after the first dose to years after ICI initiation. Most irAEs resolve pharmacologically, but some appear to be persistent. Glucocorticoids represent the mainstay of management of irAEs, but other immunosuppressive drugs can be used to mitigate refractory irAEs. In the absence of specific trials, several guidelines, based on data from retrospective studies and expert consensus, have been published to guide the management of ICI-related irAEs.<\/jats:p>","DOI":"10.3389\/fimmu.2022.804597","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T07:44:36Z","timestamp":1648626276000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":130,"title":["Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events"],"prefix":"10.3389","volume":"13","author":[{"given":"Remo","family":"Poto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Troiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gjada","family":"Criscuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Marone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda","family":"Varricchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies With Curative Potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu441","article-title":"Survival Follow-Up and Ipilimumab Retreatment of Patients With Advanced Melanoma Who Received Ipilimumab in Prior Phase II Studies","volume":"25","author":"Lebbe","year":"2014","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/Nejmoa1709684","article-title":"Overall Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer Immunotherapy Using Checkpoint Blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20182395","article-title":"Development of Immune Checkpoint Therapy for Cancer","volume":"216","author":"Fritz","year":"2019","journal-title":"J Exp Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.11.005","article-title":"Balance and Imbalance in the Immune System: Life on the Edge","volume":"41","author":"Topalian","year":"2014","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1835ni.1835","article-title":"CTLA-4 Suppresses the Pathogenicity of Self Antigen-Specific T Cells by Cell-Intrinsic and Cell-Extrinsic Mechanisms","volume":"11","author":"Ise","year":"2010","journal-title":"Nat Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders or Major Toxicity With Ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1203475420943260","article-title":"Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management","volume":"25","author":"Muntyanu","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment Outcomes of Immune-Related Cutaneous Adverse Events","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316948","article-title":"Enterocolitis Due to Immune Checkpoint Inhibitors: A Systematic Review","volume":"67","author":"Soularue","year":"2018","journal-title":"Gut"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000482","article-title":"Checkpoint Inhibitor Colitis: A New Model of Inflammatory Bowel Disease","volume":"34","author":"Siakavellas","year":"2018","journal-title":"Curr Opin Gastroenterol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-018-0346-6","article-title":"Immune-Checkpoint Inhibitor-Induced Diarrhea and Colitis in Patients With Advanced Malignancies: Retrospective Review at MD Anderson","volume":"6","author":"Wang","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse Cardiac Effects of Cancer Therapies: Cardiotoxicity and Arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0157","article-title":"Myocarditis Associated With Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action","volume":"23","author":"Neilan","year":"2018","journal-title":"Oncologist"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of Immune Checkpoint Inhibitors","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.029626","article-title":"Cardiac Toxicity of Immune Checkpoint Inhibitors: Cardio-Oncology Meets Immunology","volume":"136","author":"Varricchi","year":"2017","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.038","article-title":"Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors: It Is Now Time for Cardio-Immuno-Oncology","volume":"71","author":"Tocchetti","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI145186145186","article-title":"Immune Checkpoint Inhibitor-Associated Myocarditis: Manifestations and Mechanisms","volume":"131","author":"Moslehi","year":"2021","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11912-020-00920-z","article-title":"Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond","volume":"22","author":"Reuss","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00108","article-title":"Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis","volume":"10","author":"Su","year":"2019","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer Immunotherapy - Immune Checkpoint Blockade and Associated Endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.3390\/ijms20102560","article-title":"Autoimmune Endocrine Dysfunctions Associated With Cancer Immunotherapies","volume":"20","author":"Ferrari","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic Immune-Related Adverse Events From Cancer Immunotherapy","volume":"14","author":"Calabrese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR Points to Consider for the Diagnosis and Management of Rheumatic Immune-Related Adverse Events Due to Cancer Immunotherapy With Checkpoint Inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000540","article-title":"How We Treat Neurological Toxicity From Immune Checkpoint Inhibitors","volume":"4","author":"Spain","year":"2019","journal-title":"ESMO Open"},{"key":"B33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological Immune-Related Adverse Events With Immune Checkpoint Inhibitors, How to Manage","volume":"122","author":"Michot","year":"2019","journal-title":"Eur J Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32132","article-title":"A Systematic Review of Adverse Events in Randomized Trials Assessing Immune Checkpoint Inhibitors","volume":"145","author":"Arnaud-Coffin","year":"2019","journal-title":"Int J Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/s12885-019-5785-z","article-title":"The Safety and Tolerability of Combined Immune Checkpoint Inhibitors (Anti-PD-1\/PD-L1 Plus Anti-CTLA-4): A Systematic Review and Meta-Analysis","volume":"19","author":"Gu","year":"2019","journal-title":"BMC Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"m736","DOI":"10.1136\/bmj.m736","article-title":"Autoimmune Complications of Immunotherapy: Pathophysiology and Management","volume":"369","author":"Chan","year":"2020","journal-title":"BMJ"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002dbi18-0002","article-title":"Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0291EJE-19-0291","article-title":"Immune Checkpoint Inhibitors and Type 1 Diabetes Mellitus: A Case Report and Systematic Review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab","volume":"101","author":"de Filette","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.101370","article-title":"New Insight in Endocrine-Related Adverse Events Associated to Immune Checkpoint Blockade","volume":"34","author":"Elia","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed Immune-Related Adverse Events With Anti-PD-1-Based Immunotherapy in Melanoma","volume":"32","author":"Owen","year":"2021","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41584-020-00546-2","article-title":"Spectrum and Impact of Checkpoint Inhibitor-Induced irAEs","volume":"17","author":"Cappelli","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-Checkpoint Inhibitors: Long-Term Implications of Toxicity","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1055\/a-0843-3366","article-title":"A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated With Immune Checkpoint Inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001370","article-title":"Checkpoint Inhibitor-Associated Arthritis: A Systematic Review of Case Reports and Case Series","volume":"27","author":"Ghosh","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0590-4","article-title":"Single-Cell Immune Landscape of Human Atherosclerotic Plaques","volume":"25","author":"Fernandez","year":"2019","journal-title":"Nat Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aay18635\/43\/eaay1863","article-title":"Targeted Deletion of PD-1 in Myeloid Cells Induces Antitumor Immunity","volume":"5","author":"Strauss","year":"2020","journal-title":"Sci Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31344","article-title":"Proatherogenic Immune Responses Are Regulated by the PD-1\/PD-L Pathway in Mice","volume":"117","author":"Gotsman","year":"2007","journal-title":"J Clin Invest"},{"key":"B55","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","article-title":"Immune Checkpoint Inhibitor Therapy Aggravates T Cell-Driven Plaque Inflammation in Atherosclerosis","volume":"2","author":"Poels","year":"2020","journal-title":"JACC CardioOncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.048708","article-title":"Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in Large Arteries","volume":"142","author":"Calabretta","year":"2020","journal-title":"Circulation"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2019.08.007","article-title":"The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity","volume":"1","author":"Minasian","year":"2019","journal-title":"JACC CardioOncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01058-x","article-title":"Low Frequency of Positive Antithyroid Antibodies is Observed in Patients With Thyroid Dysfunction Related to Immune Check Point Inhibitors","volume":"42","author":"Mazarico","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216954","article-title":"Incidence, Features, and Prognosis of Immune-Related Adverse Events Involving the Thyroid Gland Induced by Nivolumab","volume":"14","author":"Yamauchi","year":"2019","journal-title":"PloS One"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous Disorders Associated With Anti-PD-1 and Anti-PD-L1 Therapy: A Retrospective Analysis Evaluating the Clinical and Histopathologic Features, Frequency, and Impact on Cancer Therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"230ra245","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1908079116","article-title":"Autoimmune Antibodies Correlate With Immune Checkpoint Therapy-Induced Toxicities","volume":"116","author":"Tahir","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular Adverse Events Associated With Anti-PD-1 Monoclonal Antibodies: Systematic Review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40425-015-0081-181","article-title":"Baseline Circulating IL-17 Predicts Toxicity While TGF-Beta1 and IL-10 are Prognostic of Relapse in Ipilimumab Neoadjuvant Therapy of Melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14363","article-title":"Predictive and Sensitive Biomarkers for Thyroid Dysfunctions During Treatment With Immune-Checkpoint Inhibitors","volume":"111","author":"Kurimoto","year":"2020","journal-title":"Cancer Sci"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 Leads to Massive Lymphoproliferation and Fatal Multiorgan Tissue Destruction, Revealing a Critical Negative Regulatory Role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key358","article-title":"Association of HLA-DRB1 Shared Epitope Alleles and Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis","volume":"58","author":"Cappelli","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14050","article-title":"Immune Checkpoint Inhibitor-Induced Type 1 Diabetes: A Systematic Review and Meta-Analysis","volume":"36","author":"Akturk","year":"2019","journal-title":"Diabetes Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2018.11.009","article-title":"Human Leukocyte Antigen Variation is Associated With Adverse Events of Checkpoint Inhibitors","volume":"107","author":"Hasan Ali","year":"2019","journal-title":"Eur J Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad1329","article-title":"Anticancer Immunotherapy by CTLA-4 Blockade Relies on the Gut Microbiota","volume":"350","author":"Vetizou","year":"2015","journal-title":"Science"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav3487","article-title":"Microbiota-Derived Peptide Mimics Drive Lethal Inflammatory Cardiomyopathy","volume":"366","author":"Gil-Cruz","year":"2019","journal-title":"Science"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline Gut Microbiota Predicts Clinical Response and Colitis in Metastatic Melanoma Patients Treated With Ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10391","article-title":"Intestinal Microbiome Analyses Identify Melanoma Patients at Risk for Checkpoint-Blockade-Induced Colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant Myocarditis With Combination Immune Checkpoint Blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-Related Adverse Events With Immune Checkpoint Blockade: A Comprehensive Review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01623-z","article-title":"T Cell Characteristics Associated With Toxicity to Immune Checkpoint Blockade in Patients With Melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 Control Over Foxp3+ Regulatory T Cell Function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.10.009","article-title":"How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity","volume":"39","author":"Liu","year":"2018","journal-title":"Trends Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01722","article-title":"Targeting Resident Memory T Cells for Cancer Immunotherapy","volume":"9","author":"Blanc","year":"2018","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0921","article-title":"Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes With PD-1 Blockade in Non-Small Cell Lung Cancer","volume":"27","author":"Luo","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11166","article-title":"Predictive Factors of Nivolumab-Induced Hypothyroidism in Patients With Non-Small Cell Lung Cancer","volume":"31","author":"Maekura","year":"2017","journal-title":"In Vivo"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13800","article-title":"Association of Antithyroglobulin Antibodies With the Development of Thyroid Dysfunction Induced by Nivolumab","volume":"109","author":"Kimbara","year":"2018","journal-title":"Cancer Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1210\/jc.2009-1365","article-title":"Clinical Applications of Diabetes Antibody Testing","volume":"95","author":"Bingley","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/srep43492","article-title":"In Situ Activation of Pituitary-Infiltrating T Lymphocytes in Autoimmune Hypophysitis","volume":"7","author":"Lin","year":"2017","journal-title":"Sci Rep"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights Into Pathogenesis From an Autopsy Series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and Activity of Anti-PD-L1 Antibody in Patients With Advanced Cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-Programmed-Death-Receptor-1 Treatment With Pembrolizumab in Ipilimumab-Refractory Advanced Melanoma: A Randomised Dose-Comparison Cohort of a Phase 1 Trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-017-4943-5","article-title":"Understanding Cytokine Release Syndrome","volume":"44","author":"Godel","year":"2018","journal-title":"Intensive Care Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00557","article-title":"Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database","volume":"11","author":"Ceschi","year":"2020","journal-title":"Front Pharmacol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0155-1","article-title":"Immune Dysregulation in Cancer Patients Developing Immune-Related Adverse Events","volume":"120","author":"Khan","year":"2019","journal-title":"Br J Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01406-6","article-title":"Gut Microbiota Signatures are Associated With Toxicity to Combined CTLA-4 and PD-1 Blockade","volume":"27","author":"Andrews","year":"2021","journal-title":"Nat Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.4.2513","article-title":"Programmed Death Ligand 1 Regulates a Critical Checkpoint for Autoimmune Myocarditis and Pneumonitis in MRL Mice","volume":"181","author":"Lucas","year":"2008","journal-title":"J Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/nm955nm955","article-title":"Autoantibodies Against Cardiac Troponin I are Responsible for Dilated Cardiomyopathy in PD-1-Deficient Mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200389","article-title":"PD-1 Protects Against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis","volume":"188","author":"Tarrio","year":"2012","journal-title":"J Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1922867117","article-title":"Polygenic Risk for Skin Autoimmunity Impacts Immune Checkpoint Blockade in Bladder Cancer","volume":"117","author":"Khan","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02254","article-title":"Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells","volume":"10","author":"Anderson","year":"2019","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac4255science.aac4255[pii","article-title":"Commensal Bifidobacterium Promotes Antitumor Immunity and Facilitates Anti-PD-L1 Efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706","article-title":"Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy Against Epithelial Tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao3290","article-title":"The Commensal Microbiome is Associated With Anti-PD-1 Efficacy in Metastatic Melanoma Patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"B105","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut Microbiome Modulates Response to Anti-PD-1 Immunotherapy in Melanoma Patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune Diseases and Immune-Checkpoint Inhibitors for Cancer Therapy: Review of the Literature and Personalized Risk-Based Prevention Strategy","volume":"31","author":"Haanen","year":"2020","journal-title":"Ann Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and Efficacy of Anti-Programmed Death 1 Antibodies in Patients With Cancer and Pre-Existing Autoimmune or Inflammatory Disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02321-z","article-title":"Pre-Existing Autoimmune Disease and the Risk of Immune-Related Adverse Events Among Patients Receiving Checkpoint Inhibitors for Cancer","volume":"68","author":"Kehl","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1210\/js.2017-00432","article-title":"Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J Endocr Soc"},{"key":"B110","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12967-018-1452-4","article-title":"Baseline Antibody Profiles Predict Toxicity in Melanoma Patients Treated With Immune Checkpoint Inhibitors","volume":"16","author":"Gowen","year":"2018","journal-title":"J Transl Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12967-018-1467-x","article-title":"Sex and Interleukin-6 are Prognostic Factors for Autoimmune Toxicity Following Treatment With Anti-CTLA4 Blockade","volume":"16","author":"Valpione","year":"2018","journal-title":"J Transl Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9679896798[pii","article-title":"Early B Cell Changes Predict Autoimmunity Following Combination Immune Checkpoint Blockade","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-","article-title":"Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated With Immune-Checkpoint Inhibitors","volume":"24","author":"Pavan","year":"2019","journal-title":"Oncologist"},{"key":"B115","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/immuno1030017","article-title":"Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients","volume":"1","author":"Giommoni","year":"2021","journal-title":"Immuno"},{"key":"B116","doi-asserted-by":"publisher","first-page":"9096","DOI":"10.1200\/jco.2014.32.15_suppl.9096","article-title":"Abstract: Correlation of Absolute and Relative Eosinophil Counts With Immune-Related Adverse Events in Melanoma Patients Treated With Ipilimumab","volume":"32","author":"Schindler","year":"2014","journal-title":"J Clin Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.02.011","article-title":"The Association Between Tumor Burden and Severe Immune-Related Adverse Events in non-Small Cell Lung Cancer Patients Responding to Immune-Checkpoint Inhibitor Treatment","volume":"130","author":"Sakata","year":"2019","journal-title":"Lung Cancer"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1465dc18-1465","article-title":"Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes","volume":"41","author":"Wright","year":"2018","journal-title":"Diabetes Care"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0238EJE-19-0238","article-title":"Hypophysitis Secondary to Nivolumab and Pembrolizumab is a Clinical Entity Distinct From Ipilimumab-Associated Hypophysitis","volume":"181","author":"Faje","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1172\/JCI131194131194","article-title":"Time to Dissect the Autoimmune Etiology of Cancer Antibody Immunotherapy","volume":"130","author":"Dougan","year":"2020","journal-title":"J Clin Invest"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0613","article-title":"The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders","volume":"7","author":"Ma","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31629","article-title":"High-Dose Glucocorticoids for the Treatment of Ipilimumab-Induced Hypophysitis is Associated With Reduced Survival in Patients With Melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"B123","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased Reporting of Fatal Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"B124","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, Monitoring and Management of Immune-Related Adverse Drug Reactions of Anti-PD-1 Antibody Therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory Eruptions Associated With Immune Checkpoint Inhibitor Therapy: A Single-Institution Retrospective Analysis With Stratification of Reactions by Toxicity and Implications for Management","volume":"80","author":"Coleman","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-Like Lesions Occurring in Patients Receiving Anti-Programmed Cell Death-1 Therapies are Clinically and Biologically Distinct From Vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1619693","article-title":"Disproportionality Analysis of Bullous Pemphigoid Adverse Events With PD-1 Inhibitors in the FDA Adverse Event Reporting System","volume":"18","author":"Aggarwal","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/diagnostics8040076","article-title":"Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data","volume":"8","author":"Soldatos","year":"2018","journal-title":"Diagnostics (Basel)"},{"key":"B130","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.annemergmed.2018.04.019","article-title":"Adverse Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer Center","volume":"73","author":"El Majzoub","year":"2019","journal-title":"Ann Emerg Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte-Associated Antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J Clin Oncol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1344805","article-title":"Incidence of Immune Checkpoint Inhibitor-Related Colitis in Solid Tumor Patients: A Systematic Review and Meta-Analysis","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy1044989161","article-title":"Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"B134","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","article-title":"Cancer Immunotherapy With Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease","volume":"10","author":"Marthey","year":"2016","journal-title":"J Crohns Colitis"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered With or Without Prophylactic Budesonide in Patients With Unresectable Stage III or IV Melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","article-title":"Infliximab Associated With Faster Symptom Resolution Compared With Corticosteroids Alone for the Management of Immune-Related Enterocolitis","volume":"6","author":"Johnson","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-1962-6","article-title":"Vedolizumab Treatment for Immune Checkpoint Inhibitor-Induced Enterocolitis","volume":"66","author":"Bergqvist","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B138","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40425-019-0577-1","article-title":"Early Introduction of Selective Immunosuppressive Therapy Associated With Favorable Clinical Outcomes in Patients With Immune Checkpoint Inhibitor-Induced Colitis","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13746","article-title":"Hepatotoxicity of Immune Checkpoint Inhibitors: An Evolving Picture of Risk Associated With a Vital Class of Immunotherapy Agents","volume":"38","author":"Suzman","year":"2018","journal-title":"Liver Int"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of Liver Injury Induced by Cancer Immunotherapy Using Immune Checkpoint Inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","article-title":"Clinical Characteristics and Outcomes of Immune Checkpoint Inhibitor-Induced Pancreatic Injury","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety Profiles of Anti-CTLA-4 and Anti-PD-1 Antibodies Alone and in Combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.3390\/ijms20163934ijms20163934","article-title":"The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition","volume":"20","author":"Varricchi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-Related Thyroiditis With Immune Checkpoint Inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies","volume":"100","author":"Orlov","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-004483805504","article-title":"Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B148","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-Term Follow-Up of Ipilimumab-Induced Hypophysitis, a Common Adverse Event of the Anti-CTLA-4 Antibody in Melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A1623","article-title":"Ipilimumab-Induced Hypophysitis: MR Imaging Findings","volume":"30","author":"Carpenter","year":"2009","journal-title":"AJNR Am J Neuroradiol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-12-0167","article-title":"Ipilimumab: A Novel Immunomodulating Therapy Causing Autoimmune Hypophysitis: A Case Report and Review","volume":"167","author":"Juszczak","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053745","article-title":"The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma From the Ipilimumab Network","volume":"8","author":"Voskens","year":"2013","journal-title":"PloS One"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune Checkpoint Inhibitors: An Emerging Cause of Insulin-Dependent Diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1331dc15-1331","article-title":"Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes","volume":"38","author":"Gaudy","year":"2015","journal-title":"Diabetes Care"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0889dc15-0889","article-title":"Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes","volume":"38","author":"Mellati","year":"2015","journal-title":"Diabetes Care"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-234938\/4\/e55","article-title":"Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.2337\/dbi19-002269\/7\/1311","article-title":"T-Cell Epitopes and Neo-Epitopes in Type 1 Diabetes: A Comprehensive Update and Reappraisal","volume":"69","author":"James","year":"2020","journal-title":"Diabetes"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2033-8","article-title":"Autoimmune Diabetes Induced by PD-1 Inhibitor-Retrospective Analysis and Pathogenesis: A Case Report and Literature Review","volume":"66","author":"Gauci","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in Patients Treated With Anti-Programmed Death-1\/Programmed Death Ligand 1 Therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab Versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab Versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.24532544610","article-title":"Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-Analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cllc.2019.07.006","article-title":"Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors","volume":"20","author":"Fukihara","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.09.015","article-title":"Characteristics, Incidence, and Risk Factors of Immune Checkpoint Inhibitor-Related Pneumonitis in Patients With non-Small Cell Lung Cancer","volume":"125","author":"Cho","year":"2018","journal-title":"Lung Cancer"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.01.002","article-title":"Safety and Efficacy of PD-1\/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis","volume":"19","author":"Khunger","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and Class-Specific Patterns of Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/srep44173","article-title":"PD-1 Inhibitors Increase the Incidence and Risk of Pneumonitis in Cancer Patients in a Dose-Independent Manner: A Meta-Analysis","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001298","article-title":"Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-Related Pneumonitis","volume":"43","author":"Larsen","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1579","article-title":"Risk Factors for Pneumonitis in Patients Treated With Anti-Programmed Death-1 Therapy: A Case-Control Study","volume":"7","author":"Cui","year":"2018","journal-title":"Cancer Med"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.10.001","article-title":"Pre-Existing Pulmonary Fibrosis is a Risk Factor for Anti-PD-1-Related Pneumonitis in Patients With non-Small Cell Lung Cancer: A Retrospective Analysis","volume":"125","author":"Yamaguchi","year":"2018","journal-title":"Lung Cancer"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000952","article-title":"Pneumonitis From Immune Checkpoint Inhibitors and COVID-19: Current Concern in Cancer Treatment","volume":"8","author":"Rossi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx2253958159","article-title":"Management of Toxicities From Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1159\/000509941","article-title":"Immune Checkpoint Inhibitor-Related Pneumonitis","volume":"99","author":"Gomatou","year":"2020","journal-title":"Respiration"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of Immunotherapy-Related Toxicities, Version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic Disorders Associated With Immune Checkpoint Inhibitors in Patients With Cancer-Clinical Aspects and Relationship With Tumour Response: A Single-Centre Prospective Cohort Study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23467","article-title":"Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response","volume":"71","author":"Smith","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000906","article-title":"Polymyalgia Rheumatica-Like Syndrome From Checkpoint Inhibitor Therapy: Case Series and Systematic Review of the Literature","volume":"5","author":"Calabrese","year":"2019","journal-title":"RMD Open"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.02.011","article-title":"Clinical Presentation of Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Differs by Immunotherapy Regimen","volume":"48","author":"Cappelli","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1002\/art.41587","article-title":"Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications","volume":"73","author":"Cappelli","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients With Cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation"},{"key":"B186","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and Neuromuscular Side-Effects Induced by Immune Checkpoint Inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000196","article-title":"PD-1 Inhibitor-Associated Myopathies: Emerging Immune-Mediated Myopathies","volume":"41","author":"Liewluck","year":"2018","journal-title":"J Immunother"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.05.006","article-title":"Myositis as an Adverse Event of Immune Checkpoint Blockade for Cancer Therapy","volume":"48","author":"Shah","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1313140","article-title":"Cancer-Drug Discovery and Cardiovascular Surveillance","volume":"369","author":"Groarke","year":"2013","journal-title":"N Engl J Med"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in Patients Treated With Immune Checkpoint Inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz0265304411[pii","article-title":"Cardiovascular Toxicities Associated With Immune Checkpoint Inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular Toxicities Associated With Immune Checkpoint Inhibitors: An Observational, Retrospective, Pharmacovigilance Study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune Checkpoint Inhibitor-Induced Myositis, the Earliest and Most Lethal Complication Among Rheumatic and Musculoskeletal Toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B194","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering Myocarditis Following Immune Checkpoint Blockade","volume":"5","author":"Norwood","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B195","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2018.03.012","article-title":"Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area","volume":"34","author":"Mir","year":"2018","journal-title":"Can J Cardiol"},{"key":"B197","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing Toxicities Associated With Immune Checkpoint Inhibitors: Consensus Recommendations From the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N Engl J Med"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.9309893098","article-title":"Insulin Supplementation Attenuates Cancer-Induced Cardiomyopathy and Slows Tumor Disease Progression","volume":"2","author":"Thackeray","year":"2017","journal-title":"JCI Insight"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab4306352226","article-title":"Targeting Early Stages of Cardiotoxicity From Anti-PD1 Immune Checkpoint Inhibitor Therapy","volume":"43","author":"Michel","year":"2022","journal-title":"Eur Heart J"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab5846359545[pii","article-title":"Novel Actors on the Stage of Cardiac Dysfunction Induced by Anti-PD1 Oncological Treatments","volume":"43","author":"Varricchi","year":"2021","journal-title":"Eur Heart J"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological Adverse Events Associated With Immune Checkpoint Inhibitors: Review of the Literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"key":"B203","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic Toxicity Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Study","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological Immune-Related Adverse Events Induced by Anti-PD-1 or Anti-PD-L1 Immunotherapy: A Descriptive Observational Study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological Immune Related Adverse Events After Treatment With Immune Checkpoint Inhibitors","volume":"147","author":"Kramer","year":"2021","journal-title":"Eur J Cancer"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25448","article-title":"Clinical and Laboratory Features of Autoimmune Hemolytic Anemia Associated With Immune Checkpoint Inhibitors","volume":"94","author":"Leaf","year":"2019","journal-title":"Am J Hematol"},{"key":"B207","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, Gastrointestinal, Hepatic, Endocrine, and Renal Side-Effects of Anti-PD-1 Therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2016.12.004","article-title":"Renal Complications of Immune Checkpoint Blockade","volume":"41","author":"Murakami","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse Effects of Immune-Checkpoint Inhibitors: Epidemiology, Management and Surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological Features of Acute Kidney Injury Associated With Immune Checkpoint Inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"B211","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of Immune Checkpoint Inhibitors Beyond Tubulointerstitial Nephritis: Single-Center Experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000296","article-title":"Ocular and Orbital Side-Effects of Checkpoint Inhibitors: A Review Article","volume":"28","author":"Antoun","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.701951","article-title":"Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.02.012","article-title":"Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1\/PD-L1 Anticancer Immunotherapy","volume":"202","author":"Bitton","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1583347","article-title":"Ocular Adverse Events Following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies","volume":"28","author":"Noble","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca Syndrome Associated With Immune Checkpoint Inhibitor Therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncologist"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab Versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and Ipilimumab Versus Ipilimumab in Untreated Melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2238","article-title":"Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options","volume":"2","author":"Khan","year":"2016","journal-title":"JAMA Oncol"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.7326\/M17-20732667695","article-title":"Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1002\/art.41068","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 Inhibitor-Induced Thyroiditis Is Associated With Better Overall Survival in Cancer Patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"B226","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1509660","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000745","article-title":"Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association","volume":"141","author":"Kociol","year":"2020","journal-title":"Circulation"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007405","article-title":"Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document","volume":"13","author":"Ammirati","year":"2020","journal-title":"Circ Heart Fail"},{"key":"B230","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3390\/cancers12030546","article-title":"Association of Steroids Use With Survival in Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"12","author":"Petrelli","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.06.004","article-title":"Early Use of Systemic Corticosteroids in Patients With Advanced NSCLC Treated With Nivolumab","volume":"13","author":"Scott","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000457","article-title":"Modulation of Peripheral Blood Immune Cells by Early Use of Steroids and its Association With Clinical Outcomes in Patients With Metastatic non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors","volume":"4","author":"Fuca","year":"2019","journal-title":"ESMO Open"},{"key":"B234","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1684\/ejd.2014.2471","article-title":"Single-Center Study Under a French Temporary Authorization for Use (TAU) Protocol for Ipilimumab in Metastatic Melanoma: Negative Impact of Baseline Corticosteroids","volume":"25","author":"Chasset","year":"2015","journal-title":"Eur J Dermatol"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00189","article-title":"Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32080","article-title":"Differential Effects of Corticosteroids and Anti-TNF on Tumor-Specific Immune Responses: Implications for the Management of irAEs","volume":"145","author":"Draghi","year":"2019","journal-title":"Int J Cancer"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3322","article-title":"Association of Anti-TNF With Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry","volume":"26","author":"Verheijden","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000268","article-title":"Incidence and Clinical Impact of Anti-TNFalpha Treatment of Severe Immune Checkpoint Inhibitor-Induced Colitis in Advanced Melanoma: The Mecolit Survey","volume":"42","author":"Lesage","year":"2019","journal-title":"J Immunother"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00584-4","article-title":"TNF in the Era of Immune Checkpoint Inhibitors: Friend or Foe","volume":"17","author":"Chen","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B240","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41584-021-00640-z","article-title":"TNF Inhibition for Immune Checkpoint Inhibitor-Induced irAEs: The Jury is Still Out","volume":"17","author":"Suijkerbuijk","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF Blockade Uncouples Efficacy and Toxicity in Dual CTLA-4 and PD-1 Immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001459","article-title":"First Report of De Novo Nivolumab-Induced Oligoarthritis in a Young Man With Relapsing Classic Hodgkin Lymphoma","volume":"27","author":"Galdiero","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-020-00827-8","article-title":"Control of Immunity by Glucocorticoids in Health and Disease","volume":"42","author":"Shimba","year":"2020","journal-title":"Semin Immunopathol"},{"key":"B245","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s40425-019-0711-0","article-title":"Concurrent Therapy With Immune Checkpoint Inhibitors and TNFalpha Blockade in Patients With Gastrointestinal Immune-Related Adverse Events","volume":"7","author":"Badran","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2019190036","article-title":"Immune Checkpoint Inhibitor Therapy-Related Pneumonitis: Patterns and Management","volume":"39","author":"Kalisz","year":"2019","journal-title":"Radiographics"},{"key":"B247","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.it.2021.02.006","article-title":"Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines","volume":"42","author":"Kang","year":"2021","journal-title":"Trends Immunol"},{"key":"B248","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","article-title":"Outcomes of Vedolizumab Therapy in Patients With Immune Checkpoint Inhibitor-Induced Colitis: A Multi-Center Study","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B249","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0484-x","article-title":"Complete Response of Metastatic Melanoma in a Patient With Crohn\u2019s Disease Simultaneously Receiving Anti-Alpha4beta7 and Anti-PD1 Antibodies","volume":"7","author":"Frohne","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx252","article-title":"Rituximab for Nivolumab Plus Ipilimumab-Induced Encephalitis in a Small-Cell Lung Cancer Patient","volume":"28","author":"Ito","year":"2017","journal-title":"Ann Oncol"},{"key":"B252","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejca.2018.07.125","article-title":"Rituximab in the Treatment of Pembrolizumab-Induced Myasthenia Gravis","volume":"102","author":"Crusz","year":"2018","journal-title":"Eur J Cancer"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000750","article-title":"Checkpoint Inhibitor-Related Renal Vasculitis and Use of Rituximab","volume":"8","author":"Mamlouk","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217745144","article-title":"Tocilizumab for the Management of Immune Mediated Adverse Events Secondary to PD-1 Blockade","volume":"25","author":"Stroud","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211560","article-title":"Successful Treatment of Arthritis Induced by Checkpoint Inhibitors With Tocilizumab: A Case Series","volume":"76","author":"Kim","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1703047","article-title":"Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade","volume":"376","author":"Esfahani","year":"2017","journal-title":"N Engl J Med"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0682","article-title":"IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity From Immunotherapy","volume":"7","author":"Johnson","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0238-9","article-title":"Fecal Microbiota Transplantation for Refractory Immune Checkpoint Inhibitor-Associated Colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Nat Med"},{"key":"B259","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40959-021-00095-x","article-title":"Treatment of Corticosteroid Refractory Immune Checkpoint Inhibitor Myocarditis With Infliximab: A Case Series","volume":"7","author":"Zhang","year":"2021","journal-title":"Cardiooncology"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001887","article-title":"Intensified Immunosuppressive Therapy in Patients With Immune Checkpoint Inhibitor-Induced Myocarditis","volume":"8","author":"Cautela","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B261","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1056\/NEJMc1801663","article-title":"Adverse Events Associated With Immune Checkpoint Blockade","volume":"378","author":"Kumar","year":"2018","journal-title":"N Engl J Med"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.302317","article-title":"Innate Immunity and the Failing Heart: The Cytokine Hypothesis Revisited","volume":"116","author":"Mann","year":"2015","journal-title":"Circ Res"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1138","article-title":"The Innate Immune System in Chronic Cardiomyopathy: A European Society of Cardiology (ESC) Scientific Statement From the Working Group on Myocardial Function of the ESC","volume":"20","author":"Frantz","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"B264","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab Versus Adalimumab for Moderate-To-Severe Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.712915","article-title":"Gut Microbiome and Common Variable Immunodeficiency: Few Certainties and Many Outstanding Questions","volume":"12","author":"Varricchi","year":"2021","journal-title":"Front Immunol"},{"key":"B268","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12879-015-0930-z","article-title":"Effectiveness of Fecal-Derived Microbiota Transfer Using Orally Administered Capsules for Recurrent Clostridium Difficile Infection","volume":"15","author":"Hirsch","year":"2015","journal-title":"BMC Infect Dis"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.17077","article-title":"Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium Difficile Infection: A Randomized Clinical Trial","volume":"318","author":"Kao","year":"2017","journal-title":"JAMA"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.13875","article-title":"Oral, Capsulized, Frozen Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection","volume":"312","author":"Youngster","year":"2014","journal-title":"JAMA"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.3791\/52154","article-title":"Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. Difficile Infection","author":"Allegretti","year":"2014","journal-title":"J Vis Exp"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.01.007","article-title":"Success of Self-Administered Home Fecal Transplantation for Chronic Clostridium Difficile Infection","volume":"8","author":"Silverman","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy7215078604","article-title":"Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection: A Systematic Review and Meta-Analysis","volume":"68","author":"Tariq","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318320","article-title":"Donor Metabolic Characteristics Drive Effects of Faecal Microbiota Transplantation on Recipient Insulin Sensitivity, Energy Expenditure and Intestinal Transit Time","volume":"69","author":"de Groot","year":"2020","journal-title":"Gut"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00002","article-title":"The Super-Donor Phenomenon in Fecal Microbiota Transplantation","volume":"9","author":"Wilson","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"B276","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/apt.16148","article-title":"Systematic Review: The Global Incidence of Faecal Microbiota Transplantation-Related Adverse Events From 2000 to 2020","volume":"53","author":"Marcella","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321829","article-title":"Reorganisation of Faecal Microbiota Transplant Services During the COVID-19 Pandemic","volume":"69","author":"Ianiro","year":"2020","journal-title":"Gut"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving Towards Personalized Treatments of Immune-Related Adverse Events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00496-y","article-title":"Anti-Angiogenic Agents - Overcoming Tumour Endothelial Cell Anergy and Improving Immunotherapy Outcomes","volume":"18","author":"Huinen","year":"2021","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.804597\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T07:44:42Z","timestamp":1648626282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.804597\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":279,"alternative-id":["10.3389\/fimmu.2022.804597"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.804597","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,30]]},"article-number":"804597"}}